GlassScriptPhysician profile
Amit A Patel
NPI 1598076184
$7,098.81
in general payments reported to CMS, 2019-2025
33 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 85% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $683 · 2021: $835 · 2022: $1,278 · 2023: $1,007 · 2024: $1,066 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,425.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,192.55 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Optinose US, INC. | $1,130.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,011.77 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $915.82 | 2019-2025 | Dupixent |
| Genzyme Corporation | $740.95 | 2019-2025 | |
| Pfizer INC. | $304.27 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.03 | 2019-2022 | |
| Abbvie INC. | $170.05 | 2021-2025 | |
| Stryker Corporation | $160.29 | 2019-2025 | Xpress Loprofile |
| Daiichi Sankyo INC. | $150.49 | 2020-2022 | |
| Inspire Medical Systems, INC. | $148.70 | 2023-2025 | Inspire |
| Hikma Pharmaceuticals USA | $99.62 | 2023-2025 | Ryaltris, Kloxxado |
| Allergan, INC. | $99.35 | 2020 | |
| Alk-Abello, INC | $96.68 | 2019-2023 | Odactra, Grastek |
| Bayer Healthcare Pharmaceuticals INC. | $93.59 | 2022-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $78.32 | 2019-2020 | |
| Watermark Medical, INC. | $69.14 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.38 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $50.53 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $49.40 | 2020-2021 | |
| Pharming Healthcare, INC. | $35.99 | 2022 | |
| Bio Products Laboratory USA, INC. | $33.51 | 2019 | |
| Aerin Medical INC. | $29.36 | 2019-2023 | |
| Ars Pharmaceuticals Operations, INC. | $28.61 | 2025 | Neffy |
| Davol INC. | $26.86 | 2019 | |
| Eisai INC. | $26.14 | 2019 | |
| Genentech USA, INC. | $25.55 | 2019-2021 | |
| Neurent Medical Limited | $22.04 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Paratek Pharmaceuticals, INC. | $17.91 | 2025 | Xhance |
| Smith+Nephew, INC. | $16.56 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.61 | 2023 | |
| Eyevance Pharmaceuticals LLC | $12.08 | 2021 | |
| Mylan Pharmaceuticals INC. | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.